Redeye updates its estimates following Surgical Science’s Q1 2024 report, which came in considerably below our estimates due to weak Educational Products sales. In contrast, Industry/OEM exceeded our estimates. Despite strong comparables, Educational Products’ weakness surprised us. We lower our estimates for the segment and valuation.